Soligenix ( (SNGX)) has shared an announcement. On July 31, 2025, Soligenix announced the completion of its Phase 2a proof of concept study for SGX945 (dusquetide) in treating Behçet’s Disease, ...

Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company) ...

Soligenix Inc. (NASDAQ:SNGX) shares surged on Thursday as the company announced positive results from its Phase 2a ...

Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results ...

Five Dogs of the Dow stocks offer big yields, a degree of safety from tariffs, and a long history of corporate success.

The Village Voice previews the book launch of Pulitzer Prize nominee Ed Park’s short story collection “An Oral History of Atlantis.” ...

The disease's symptoms, which can include severe oral and genital ulcers, are most debilitating in young adulthood. Soligenix's focus on SGX945 reflects its broader commitment to addressing unmet ...

U.S. Oral Surgery Management 469-242-0475 robin.stevens@usosm.com The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties.

Ye is accused of grabbing his ex-assistant's genitals and forcing her to perform oral sex on him during a business trip in San Francisco.

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.